EUVIMEDEUVIMED entdecken
Crossref

Dual-tracer PSMA/FDG PET/CT for lesion detection and risk stratification in biochemical recurrence with negative conventional imaging

Linjie Bian, Xuan Huang, Bin Zhu, Chang Liu, Xiaoping Xu, Silong Hu, Shaoli Song

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-026-08089-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Linjie Bian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, No. 270 Dong'an Road, Xuhui District, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Prostatic Neoplasms, Oligopeptides. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Nuclear Technology R&D Program, Shanghai Collaborative Innovation Project, the Key Program of the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate lesion detection patterns and the risk-stratification value of paired 68Ga-PSMA-11 and 18F-FDG PET/CT in patients with post-prostatectomy biochemical recurrence (BCR) and negative conventional imaging, and to explore the hypothesis-generating biological context of dual-tracer phenotypes using public single-cell transcriptomic data. METHODS: This retrospective single-center study included patients with post-prostatectomy BCR who underwent paired 68Ga-PSMA-11 and 18F-FDG PET/CT within 14 days and had negative conventional imaging within 1 month before PET/CT. Overall dual-tracer PET positivity was defined as at least 1 positive lesion on either tracer. Among patients with PET-detectable disease on either tracer, phenotypes were classified as PSMA+/FDG-, PSMA+/FDG+, or PSMA-/FDG+. Public single-cell RNA sequencing data were analyzed to assess the relationship between FOLH1 expression and glycolytic activity. RESULTS: Among 58 included patients, 21 (36.2%) had at least one positive lesion on either tracer. Overall dual-tracer PET positivity increased across PSA strata and with a greater number of prespecified risk features (both P for trend < 0.001). Older age and higher PSA at PET were independently associated with overall dual-tracer PET positivity. Among patients with PET-detectable disease on either tracer, FDG-avid disease was associated with pathologic stage ≥pT3, pathologic N1 disease, recurrence within 3 years after radical prostatectomy, and PSA doubling time ≤ 6 months. In the public single-cell cohort, FOLH1 expression and glycolytic activity showed only a weak association. CONCLUSION: Paired 68Ga-PSMA-11 and 18F-FDG PET/CT revealed heterogeneity beyond lesion detection in patients with post-prostatectomy BCR and negative conventional imaging. Among patients with PET-detectable disease on either tracer, FDG-avid disease was enriched for adverse clinicopathologic features, and public single-cell transcriptomic analysis provided hypothesis-generating biological context for divergent dual-tracer phenotypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyFluorodeoxyglucose F18Prostatic NeoplasmsOligopeptidesHumansMaleRetrospective StudiesRisk AssessmentGallium IsotopesMiddle AgedGallium RadioisotopesAgedRadiopharmaceuticalsRecurrenceOrganometallic CompoundsAntigens, SurfaceGlutamate Carboxypeptidase II

Stichwörter der Autor:innen

18F-FDG PET/CT68Ga-PSMA-11 PET/CTBiochemical recurrenceProstate cancerRisk stratification

Substanzen

Fluorodeoxyglucose F18Gallium IsotopesFOLH1 protein, humanGallium RadioisotopesOligopeptidesgallium 68 PSMA-11RadiopharmaceuticalsOrganometallic CompoundsAntigens, SurfaceGlutamate Carboxypeptidase II

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, No. 270 Dong'an Road, Xuhui District, Shanghai, 200032, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
  • Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, 200032, China.
  • Center for Biomedical Imaging, Fudan University, Shanghai, 200032, China.
  • Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai, 200433, China.
  • Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, No. 270 Dong'an Road, Xuhui District, Shanghai, 200032, China. shaoli-song@163.com.

Förderung

  • Nuclear Technology R&D Program
  • Shanghai Collaborative Innovation Project
  • the Key Program of the National Natural Science Foundation of China
  • the Shanghai Municipal Science and Technology Commission

Zitieren

APA

Bian, L., Huang, X., Zhu, B., Liu, C., Xu, X., Hu, S., & Song, S. (2026). Dual-tracer PSMA/FDG PET/CT for lesion detection and risk stratification in biochemical recurrence with negative conventional imaging. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08089-6

Vancouver

Bian L, Huang X, Zhu B, Liu C, Xu X, Hu S, et al. Dual-tracer PSMA/FDG PET/CT for lesion detection and risk stratification in biochemical recurrence with negative conventional imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-08089-6

BibTeX
@article{Bian2026,
  author = {Bian, Linjie and Huang, Xuan and Zhu, Bin and Liu, Chang and Xu, Xiaoping and Hu, Silong and Song, Shaoli},
  title = {Dual-tracer PSMA/FDG PET/CT for lesion detection and risk stratification in biochemical recurrence with negative conventional imaging},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-026-08089-6}
}
Kostenlos starten →